Study for subjects with Ph- or Ph+ with newly diagnosed philadelphia-chromosome ALL

What we are studying

In this type of cancer there is a specific change (mutation) in the DNA that sometimes forms. The mutation is called “Philadelphia chromosome”. This study will have 2 groups: patients who do not have the Philadelphia chromosome mutation (Ph-) and patients who do have the mutation (Ph+). Treatments for the two groups will be different and are outlined below. In general, there are 3 main steps to all of the treatments. Induction/Re-Induction treatment is given first. It is a treatment given over a short period of time (usually only a few months) to get rid of as many of the leukemia cells as possible very quickly. Post-Remission treatment is given next. It is given to get rid of any leukemia cells that are left once your leukemia goes into remission and to make sure the leukemia cells don’t come back over a short period of time (usually only a few months). Maintenance treatment is given last. It is a lower dose treatment given over a long period of time (up to several years) to help keep the leukemia cells from coming back. In this type of cancer there is a specific change (mutation) in the DNA that sometimes forms. The mutation is called “Philadelphia chromosome”. This study will have 2 groups: patients who do not have the Philadelphia chromosome mutation (Ph-) and patients who do have the mutation (Ph+). Treatments for the two groups will be different and are outlined below. In general, there are 3 main steps to all of the treatments. Induction/Re-Induction treatment is given first. It is a treatment given over a short period of time (usually only a few months) to get rid of as many of the leukemia cells as possible very quickly. Post-Remission treatment is given next. It is given to get rid of any leukemia cells that are left once your leukemia goes into remission and to make sure the leukemia cells don’t come back over a short period of time (usually only a few months). Maintenance treatment is given last. It is a lower dose treatment given over a long period of time (up to several years) to help keep the leukemia cells from coming back.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 65 - 90

Eligibility Criteria

  • Newly diagnosed

What is involved

  • Ph- patients will receive standard of care chemotherapy + Blinatumomab Ph+ patients will receive prednisone
  • Dasatinib and blinatumomab

Compensation

Parking validation for all study related visits

Contact Information

Study Coordinator
Suzanne Carroll
Email
[email protected]
Phone
-5719

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.